

INDEX OF AUTHORS

- Altmann, G., 515
Amick, L. D., 54
Argyros, T. G., 368
- Baggenstoss, A. H., 298
Bahr, W. J., 129
Bauer, W., 204, 496, 522
Black, R. L., 101, 112
Blechman, W., 341
Bloch, K. J., 26, 112, 287
Bloedow, C. E., 129
Blumberg, B. S., 178, 421
Boylan, R. C., 379
Bunim, J. J., 112, 287
Burns, J. J., 475
- Calhoun, D. W., 387
Calkins, E., 101, 204
Carter, P., 204
Castor, C. W., 140
Clark, G. M., 101
Cobb, S., 91
Cohen, A. S., 522
Corcos, J., 218
Crowley, G. T., Jr., 409
Csonka, G. W., 164
- David, J. R., 112
Dayton, P. G., 475
Decker, B., 49
Deicher, H. R. G., 1
Di Fiore, J. A., 359
Dubois, E. L., 403
Duff, I. F., 64
- Ehrlich, G. E., 112
Engel, L. L., 204
Epstein, W. V., 41
- Fisher, E. R., 536
Ford, D. K., 395
Franklin, E. C., 16, 314
Freyberg, R. H., 158
Frohman, L. A., 64
- Giles, R. B., Jr., 409
Goehrs, H. R., 298
Goldenberg, A., 515
Graber, W. J., III, 309
Graham, W., 88
- Hansen, L. M., 387
Harris, J., 341
Hartung, E. F., 423
Harvey, J. P., Jr., 218
- Heimer, R., 158
Henry, M., 229
Hershberger, L. G., 387
Hollander, J. L., 101, 364
Holley, H. L., 229
Holman, H. R., 1
- Jacox, R. F., 170
Jeanloz, R. W., 233
Johns, R. J., 328
Johnson, P. C., 129
- Katz, Y. J., 403
Kunkel, H. G., 1
Kyriakopoulos, A. A., 129
- Lee, R. C., 41
Lerner, E. M., II, 26
- McGuckin, W. F., 49
McKenzie, B. F., 49
MacLachlan, M. J., 152
Mainland, D., 101
Malm, O., 341
Martel, W., 76, 546
Mikkelsen, W. M., 101
Mitchell, D. M., 204
Muller, A. F., 496
- Oglesby, R. B., 287
- Page, J. W., 546
Plotz, C. M., 515
- Ragan, C., 101
Reefe, W. E., 112
Rhineland, F. W., 561
Rodnan, G. P., 152, 195, 536
Ropes, M. W., 496
- Sanford, J. P., 309
Sayers, G., 350
Seegmiller, J. E., 475
Seidenfeld, M. A., 557
Ship, I. I., 287
Short, C. L., 101
Silberberg, D. H., 64
Silverstein, E., 485
Singer, J. M., 515
Slocumb, C. H., 49, 298
Smith, J. E., 409
Sokoloff, L., 186, 379, 485
Solomon, N., 350
Steinbrocker, O., 368
Stuart, F. S., 229

Tristan, T. M., 170

Vaughan, J. H., 341

Ward, J., 522

West, K. M., 129

Williams, R. R., Jr., 26

Wohl, M. J., 287

Wright, V., 328

Wyngaarden, J. B., 414

Young, N., 341

Ziff, M., 309

Zvaifler, N. J., 76

Zuelzer, W. W., 884

INDEX OF SUBJECTS

ACTH. *See* Steroids

Adrenal gland

after steroid therapy in rheumatoid arthritis, 240

cortical androgen secretion, Nilevar affecting, 341-347

dexamethasone affecting potencies of, 115,

135

insufficiency after abrupt cessation of cortisone, 204-216

Agar, double diffusion technics in, 16-24

Agglutination reactions

latex. *See* Latex agglutination

of nonrheumatoid sera, 277

sheep cell. *See* Sheep cells, agglutination tests

tests for rheumatoid factor, 431

See also Hemagglutination

Albumin, serum, absorption from knee, 152-157

Alkaptonuria, 238, 359-363

American Rheumatism Association

Alexander case, decision in, 97

Amsterdam Conference on social aspects of arthritis, 98

annual meeting (1960), proceedings of, 429-471

annual meeting (1961), schedule for, 567

annual meeting for business, 376

award to Dr. Lancefield, 472

Australian Association, 378

Bumim to give Heberden oration, 285

courses

in Jersey City, 472

in Seattle, 472

at University of Michigan, 98

Empire Rheumatism Council symposium, 99

European League Against Rheumatism, Istanbul Meeting, 99

fraudulent ads, report of, 472

future meetings, 377

Hartung installed as President, 284

International Congress, in Rome, 193, 377, 567-568

new members, admissions for, 378

Primer on Rheumatic Diseases, 98

publications available, 193

Rheumatism Review Committee, 285

Rome travel grants, 567

Seventh Interim Scientific Session, 285, 377, 471

Sixth Interim Scientific Session, 97, 238-284

Amines, effects on connective tissue, 447

Ammion tissue culture, and PPLO isolation, 395-401

Anemia, of rheumatoid arthritis, 460

Antibodies

antinuclear, in experimental animals, 439

response pattern in rheumatic disease, 455

Antigen-antibody complexes

absorbing rheumatoid factor preparations, 439

and gamma globulin, 17

and hypersensitivity lesions, 470

Antigens

cytoplasmic, in diseases, 1-13

factors in rheumatoid arthritis, 158

joint, in attempted experimental lupus erythematosus, 403-407

Anturan therapy, 374, 482

Aorta, mucopolysaccharides of, 452

Arabinose, entrance into joints, 504

Arthritis

feet in differential diagnosis of, 435

history of, 421-422

research, creativity in, 423-428

synovial fluid studies, 364-367

ulcerative colitis with, 282

See also specific types of arthritis

Arthrograms, in leg cysts with rheumatoid arthritis, 218-228

Aspirations, joint, technics of, 364-365

Atlanto-axial subluxation, in rheumatoid arthritis, 446, 546-555

Atrophy, muscular, in rheumatoid arthritis, 54-61

Baker's cyst, with rheumatoid arthritis, 218-228

Basophil count, in rheumatoid arthritis, 434

Bentonite flocculation test

in experimental arthritis, 26-39

in rheumatoid arthritis, juvenile, 469

in Sjogren's syndrome, 288

Biliary cirrhosis, anti-cytoplasmic factors in sera of patients with, 1-13

Blood group substances, 233

- Bone necrosis, aseptic
 hip deterioration and femoral head collapse in, 463
 in lupus erythematosus, 442
- Book reviews
 Arthritis, General Principles, Physical Medicine,
 Rehabilitation (*Lowman, ed.*), 473
 Arthritis: Medical Treatment and Home Care (*Bland*), 570
 Gouty Arthritis and Gout (*Weiss & Segaloff*), 473
 Lymphocytes and Mast Cells (*Kelsall & Crabb*), 474
 Re-education of the Injured Shoulder (*Brookes*), 99
- Breast carcinoma, metastatic to foot bones, 170-176
- Butazolidin. *See* Phenylbutazone
- Calcium balance
 after cortisone therapy cessation, 212
 in rheumatoid disease, Nilevar affecting, 341-347
- Carbohydrates
 dexamethasone affecting metabolism, 119-121
 of synovial fluid, 409-413
- Carcinoma
 breast, metastatic to foot bones, 170-176
 prostate, rheumatic symptoms with, 449
- Cardiac lesions, in rheumatoid arthritis, 298-307
- Cartilage
 bovine nasal, 246
 chondroitin sulfate in, 409
 matrix depletion in hypervitaminosis A, 253
 papain affecting, 455
- Cataracts, after corticosteroid therapy, 432
- Cells
 anti-cytoplasmic factors in sera of patients with diseases, 1-13
 rheumatoid factor in, 262
- Synovial, 142-146
 chromosomes in, 436
 cultures of, 267
 staining of, 448
 See also specific cells
- Cervical vertebra. *See* Spine
- Chitin, 236
- Chloride excretion, after dexamethasone, 132-135
- Chloroquine therapy, in rheumatoid arthritis, 470
- Chondritis, relapsing, 278
- Chondroitin sulfate, 234
 in aorta, 452
 in cartilage, 409
 in latex fixation test, 158-163
- Chromium, radioactive, clearance from knee, 195-203
- Chromosomes, in cells from synovial tissue, 436
- Cirrhosis, biliary, anti-cytoplasmic factors in sera of patients with, 1-13
- Cold
 cryoglobulins in lupus erythematosus, 449
- experimental injury, and fibrinoid necrosis, 453
- Colitis, ulcerative
 arthritis with, 282
 spondylitis with, 76-86
- Collagen
 dermal, changes in scleroderma, 541
 fibers, synovial, 146
 lysine in mineralization of, 250
 synthesis by fibroblasts in tissue culture, 267
 synthetic activity, and RNA production, 252
- Complement fixation reactions, and cytoplasmic cellular constituents in disease, 1-13
- Connective tissue
 cells, synovial, unclassified, 145
 development in polyvinyl sponges, 433
 disorders, stiffness in, 255
 growing, nucleic acids in, 252
 hexosamine concentrations in, 409-413
 metabolism, therapeutic agents affecting, 434
 papain affecting, 440
 proliferation, serotonin affecting, 447
 in Whipple's disease, 438
- Correspondence, 100, 568-570
- Corticosteroids. *See* Steroids
- Cryoglobulins, in lupus erythematosus, 449
- Cysts, in leg, with rheumatoid arthritis, 218-228
- Denervation, sympathetic, in intractable pain, 450
- Dermatan sulfate, 235
- Dermatomyositis
 muscle fiber degeneration in, 60
 vascular lesions in, 379-385
- Dermotoidin sulfate, 234
- Desoxyribonuclease (DNase), in tissue preparations, and complement fixation titer, 1-13
- Desoxyribonucleic acid (DNA)
 antibodies against, in lupus erythematosus, 403-407
 clot inhibition by L.E. serum, 256
 and experimental lupus erythematosus, 439
 of growing connective tissue, 252
 and NP-E hemagglutination, 43, 45
 serum reactant to, in lupus erythematosus, 458
- Dexamethasone therapy, 112-126
 adrenal suppressive potencies of, 115, 135
 cataracts after, 432
 eosinopenic potency of, 129-138
 hormonal effects of, 114-122, 129
 hyperglycemic effect of, 119, 129-138
 peptic ulcer after, 442
 physiologic effects of, 129-138
 side effects of, 122-125
 water and electrolyte excretion after, 132-135
- Dextran, interaction with rheumatoid factor, 443

- Diabetes
feet changes in, 436
and stiff-man syndrome, 231
- Diabetogenic properties of dexamethasone, 119
- Diagnostic criteria, 91-95
- Differential diagnosis of arthritis, feet in, 435
- Dinitrophenol, effects on entrance of glucose into joints, 506
- Elastic fibers, synovial, 146
- Electrodiagnosis of muscle atrophy in arthritis, 54-61
- Endothelial cells, synovial, 145
- Erosions, cervical vertebral, in rheumatoid arthritis, 546-555
- Erythema nodosum, acute phase reactants in, 49-52
- Erythrocytes, labeled, clearance from knee joint, 195-203
- Experimental arthritis, 186-190
bentonite flocculation test in, 26-39
DNA and joint antigens in, 403-407
from Freund's adjuvants, 485-494
immunization to, 387-393
pathogenesis of, 463
- Experimental hemarthrosis, 195-203
- Experimental lupus erythematosus, 259, 403-407, 439
- Experimental obesity and osteoarthritis, 465
- Family studies
in lupus erythematosus, 244, 445, 460
in rheumatoid arthritis, 178-182, 437
See also Twins
- Fasting, effects on uric acid excretion, 280
- Feet
breast carcinoma metastases in, 170-176
in differential diagnosis of arthritis, 435
- Femoral head, collapse of, 463
- Fibrinoid necrosis of blood vessels and connective tissue, 453
- Fibroblasts, and mucopolysaccharide synthesis, 267
- Flexin, uricosuric effects of, 482
- Fluorescent techniques
antibody studies in Sjogren's syndrome, 289
- antiglobulin studies of serum reactant to DNA in lupus erythematosus, 458
- antisera identifying streptococci, 261
- staining of rheumatoid leukocytes, 450
- Fructose, entrance into joints, 501
- G-27202, therapy with, 374
- G-28315, therapy with, 374
- G-29701, uricosuric effect of, 281, 475-483
- Galactosamine, in synovial fluid, 409-413
- Galactose, entrance into joints, 501
- Gamma globulins
absorption from knee, 152-157
aggregated, 268
and antigen-antibody complexes, 439
dye-labeled, and rheumatoid sera, precipitates between, 272
precipitin for, 270
- reaction with rheumatoid leukocytes, 450
- and experimental lupus erythematosus, 439
- inhibiting sheep-cell agglutination reaction, 314-326
- in latex fixation test, 158
- and latex particles, 273, 515-520
- and NP-E hemagglutination test, 43
- in relatives of patients with lupus erythematosus, 244
- in rheumatoid arthritis, 264
- rheumatoid arthritis with hypogammaglobulinemia, 274
- and rheumatoid factors, reaction between, 16-24, 444
- and serologic reactions in diseases, 1-13
- Genetics
and alkaptonuria, 238
- and rheumatoid arthritis, 178-184, 437, 446
- See also Family studies*
- Genital tracts, PPLO isolation from, 395-401
- Glucosamine, in synovial fluid, 409-413
- Glucose
entrance into joints, 496-513
in experimental production of L.E.-like disease, 259
- tolerance in stiff-man syndrome, 231
- utilization, dexamethasone affecting, 119-121, 136
- Glycine, and uric acid excretion in gout, 448
- Glycogen deposition, dexamethasone affecting, 119
- Glycopeptide, 236
- Glycopolyptides, 233
- Glycoproteins, 233, 236
in rheumatic diseases, 49-52
- Gm serum in rheumatoid arthritis, 465
- Gold therapy, affecting connective tissue metabolism, 434
- Genococcal arthritis, sex incidence of, 309-312
- Gout
hyperuricemia in, 414-419
kidney in, 466
in medical art, 461
trimethylcolchicinic acid in, 469
urate crystals in synovial fluid, 454
uric acid excretion in, glycine affecting, 448
- Ground substance, synovial, 146
- Hand, rheumatoid, surgery of, 437
- Hartung, Edward, 284, 424
- Heart lesions in rheumatoid arthritis, 298-307
- Heart-lung preparation, rat, 350-358
- Hemagglutination studies
of L.E. cell formation, 257
- nucleoprotein extract, 41-47
- Hemarthrosis, experimental, 195-203
- Hemophilia, hemarthrosis with, 195-203
- Heparin, 234
in latex fixation test, 158-163
- Hepatitis, in aorta, 452
- Hepatitis, lupoid, sera of patients with, 2

- Heredity conditions. *See* Genetics
Hexaminecobaltic chloride, and DNA clot formation, 256
Hexosamine
 in aorta, 452
 in rheumatic diseases, 49-52
 in synovial fluid, 409-413
Hexose, protein-bound, in rheumatic diseases, 49-52
Hip joint, deterioration of, 463
Histamine, effects on connective tissue, 448
Histone, reacting with DNA, 256
History of arthritis and rheumatism, 421-422
Homogenetic acid oxidase deficiency, 359-363
Human fraction II, aggregated, 268, 270, 272, 439, 450
Hyaluronate
 in aorta, 452
 in synovial fluid, 247
Hyaluronic acid, 235, 236
 in latex fixation test, 158
 in synovial fluid, 409, 459
 and tissue permeability, 458
Hyaluronidase, effects on clearance of radioactivity, 195-203
Hydralazine
 effects on connective tissue, 448
 lupus erythematosus after, 464
Hydrocortisone
 effects on clearance of radioactivity, 195-203
 physiologic effects of, 129-138
Hydroxyapatite, on collagen fibers, 250
Hypertensives, heat stable rheumatoid factor in, 435
Hypospray technic for intra-articular injection, 430

Immobilization
 effects on clearance of radioactivity, 195-203
 splinting, in rheumatoid arthritis, 462
Immunization to arthritis, 387-393
Immunological reactions, in Sjogren's syndrome, 433
Infectious arthritis, acute phase reactants in, 49-52
Inflammation, measurements of, 49-52
Injections, intra-articular, hypospray technic for, 430
Intimal cells, synovial, 142-145
Iproniazid, effects on connective tissue, 448
Iron, radioactive, clearance from knee, 195-203
Isoniazid, effects on connective tissue, 448

Joints
 glucose and sugars in, 496-513
 in hyperparathyroidism, 471
 injections in, hypospray technic for, 430
 in sarcoidosis, 453
 stiffness in. *See* Stiffness

Keratosulfate, 236
Kidney
 in gout, 466

in lupus erythematosus, 461
Knee
 cysts with rheumatoid arthritis, 218-228
 osteoarthritis of, 561-563, 564-566
 radiochromium and radioiron clearance from, 195-203
 serum albumin and gamma globulin absorption from, 152-157

Latex agglutination
 patterns of, 435
 in serum and synovial fluid, 447
Latex fixation test
 in juvenile rheumatoid arthritis, 469
 in leprosy, 436
 mucopolysaccharides in, 158-163
 in rheumatoid arthritis, inhibitors and stabilizers of, 432
Latex particles
 binding protein, 273
 sensitized by gamma globulin, 515-520
L.E. cell formation
 extracellular material in, 466
 factors in, 1, 41-47
 hemagglutination studies, 257
Leg
 cysts, with rheumatoid arthritis, 218-228
 ulcers, in rheumatoid arthritis, therapy of, 430
Leprosy, latex fixation test in, 436
Leukemia, with spondylitis treated with x-ray, 64-74
Leukocytes
 basophil, in rheumatoid arthritis, 434
 L.E. serum affecting, 444
 rheumatoid, reaction with aggregated gamma globulin, 450
Lupus erythematosus
 acute phase reactants in, 49-52
 anti-cytoplasmic factors in sera of patients with, 1-13
 attempts to produce, 259, 403-407
 bone necrosis in, avascular, 442
 cryoglobulins in, 449
 and DNA clot inhibition, 256
 drug-induced, 464
 experimental, antinuclear antibodies in, 439
 familial occurrence of, 460
 hypergammaglobulinemia in relatives of patients with, 244
 inhibition of lupus factor, 43
 para-toluene sulfonic acid test in, 467
 relatives of patients with, 439, 445, 460
 renal lesion in, 461
 serum affecting leukocytes, 444
 serum reactant to DNA in, 458
 skin test in, 431
 See also L.E. cell formation
Lymphosarcoma, Murphy rat, arthritogenic activity of exudate, 387-393
Lysine, in mineralization of collagen, 250
Magnesium excretion, after dexamethasone, 135
Marsilid, effects on connective tissue, 448
Mast cells
 blood, in rheumatoid arthritis, 434

- synovial, 145
 Measles, and arthritis, 451
 Medrol, evaluation of, 284
 Mesothelioma, pleural, arthropathy with, 443
 Metastatic bone lesions, 170-176
 Mineral metabolism, in rheumatoid disease, Nilevar affecting, 341-347
 Mineralization of collagen, lysine in, 250
 Mucin, 233
 Mucoids, 233
 Mucopolysaccharides of aorta, 452
 in latex fixation test, 158-163
 nomenclature of, 233-237
 in sclerodermatous skin, 541
 synthesis by fibroblasts in tissue culture, 267
 Mucopolyuronides, 233
 Mucoproteins, 233
 Muscles
 atrophy in rheumatoid arthritis, electro-diagnosis of, 54-61
 dermatomyositis, 60, 379-385
 polymyositis, 441
 rigidity in stiff-man syndrome, 229-231
 Mycoplasmal polyarthritides, and tumor regression, 260

 Nasal cartilage, bovine, 246
 Necrosis
 bone
 hip deterioration and femoral head collapse in, 463
 in lupus erythematosus, 442
 fibrinoid, of blood vessels and connective tissue, 453
 Nerves, sympathetic denervation in intractable pain, 450
 Nilevar, effects on metabolism in rheumatoid disease, 341-347
 Nitrogen balance
 after cortisone therapy cessation, 212
 in rheumatoid disease, Nilevar affecting, 341-347
 Nonrheumatoid sera, properties of, 277
 Nucleic acids, of growing connective tissue, 252
 Nucleoprotein extract, hemagglutination test, 41-47

 Obesity, experimental, and osteoarthritis, 465
 Ochronosis, 359-363
 pathogenesis of, 457
 Osteoarthritis
 acute phase reactants in, 49-52
 and experimental obesity, 465
 of knee, 561-563, 564-566
 Osteoarthropathy, hypertrophic and intrathoracic disease, 443
 pulmonary, acute phase reactants in, 49-52
 Osteochondritis, spinal in twins, with spondylitis, 444
 Oxyphenbutazone, keto analog of, uricosuric effect of, 281, 475-483

 Pain, intractable, sympathetic denervation in, 450
 Papain
 effects on cartilage, 455
 effects on connective tissue, 440
 Parathyroid disorders, joints in, 471
 Para-toluene sulfonic acid test, evaluation of, 467
 Peptic ulcer, after corticosteroids, 442
 Periarteritis nodosa, 456
 Periarthritis, experimental production of, 485-494
 Pharyngitis, streptococcal, and rheumatic fever, 464
 Phenylbutazone therapy, 368-374
 synovial tissue after, 445
 Phloridzin, affecting entrance of glucose into joints, 506
 Phosphorus balance
 after cortisone therapy cessation, 212
 in rheumatoid disease, Nilevar affecting, 341-347
 Pituitary
 dexamethasone affecting activity of, 115
 from polyarteritic animals, transplants of, 239
 function after steroid therapy in rheumatoid arthritis, 240
 Platelets, redox activity of, on addition of serotonin, 452
 Pleural mesothelioma, arthropathy with, 443
 Pleurepneumonia-like organisms (PPLO)
 in experimental arthritis, 463
 neutralization of, 387-393
 in polyarthritis, 260
 in urethritis with arthritis, 395-401
 Polyarteritis nodosa, induction of, 239
 Polyarthritides, mycoplasmal, and tumor regression, 260
 Polychondritis, relapsing, 278
 Polymyositis, 441
 electromyography in, 60
 Polysaccharides, 233
 interaction with rheumatoid factor, 443
 Popliteal cysts, with rheumatoid arthritis, 218-228
 Potassium excretion, after dexamethasone, 135
 Precipitin reaction, between rheumatoid factors and gamma globulin, 16-24
 Prednisolone and prednisone
 cataracts after, 432
 peptic ulcer after, 442
 physiologic effects of, 129-138
 Pressure gradient therapy of leg ulcers in rheumatoid arthritis, 430
 Prostate carcinoma, rheumatic symptoms with, 449
 Proteins
 cryoglobulins in lupus erythematosus, 449
 glycoproteins, 49-52, 233, 236
 metabolism in rheumatoid disease, Nilevar affecting, 341-347
 serum
 permeability of synovium to, 152-157
 in rheumatic diseases, 49-52
 and serologic reactions in diseases, 1-13
 in Sjogren's syndrome, 288

- in synovial fluid, and hyaluronic acid, 459
See also Gamma globulin
- Psoriatic arthritis, 429
feet in, 435
- Psychological factors in rheumatoid arthritis, 456
- Radiation therapy, in rheumatoid spondylitis, leukemia after, 64-74
- Radiology
of Reiter's syndrome, 469
of spondylitis and rheumatoid arthritis, 441
- Reactants, acute phase, in rheumatic diseases, 49-52
- Recurrent attacks, in Reiter's disease, 164-169
- Redox activity of platelets, on addition of serotonin, 452
- Rehabilitation centers, selection of, 557-560
- Reiter's syndrome
acute phase reactants in, 49-52
cutaneous signs of, 469
diagnosis of, 312
PPLLO in, 395-401
radiology of, 469
recurrent attacks in, 164-169
- Research in arthritis, creativity in, 423-428
- Reticular fibers, synovial, 147
- Rheumatic diseases
acute phase reactants in, 49-52
antibody response in, 455
- Rheumatic fever
case registry in Dade County, 462
chronic, 466
and streptococcal pharyngitis, 464
- Rheumatic symptoms, with carcinoma of prostate, 449
- Rheumatism, history of, 421-422
- Rheumatoid arthritis
acute phase reactants in, 49-52
anemia of, 460
anti-cytoplasmic factors in sera of patients with, 1-13
antigenic factors in, 158
basophil leukocytes in, 434
cardiac lesions in, 298-307
cataracts after corticosteroid therapy, 432
cervical spine lesions in, 446, 454, 546-555
chloroquine therapy, 470
cortisone therapy, abrupt cessation of, 204-216
dexamethasone in, 112-126
experimental, 403-407
feet in, 435
and fibrinoid necrosis, 453
gamma globulin complexes in sera, 264
and genetics, 178-184
Gm serum in, 465
hypogammaglobulinemia with, 274
juvenile, serological tests in, 469
latex agglutination in serum and synovial fluid, 447
latex fixation test for inhibitor and stabilizer of, 432
leg cysts with, 218-228
leg ulcers with, therapy of, 430
- long-term steroid therapy, 451
muscle atrophy in, electrodiagnosis of, 54-61
- Nilevar affecting metabolism in, 431-437
occasional attacks of, 438
pituitary-adrenal function after steroid therapy, 240
- psychosocial factors in, 456
- roentgen features of, 441
and rubella arthritis, 451
- sensitized sheep-cell agglutination reaction in, 266
splinting in, 462
- sugars entering joints in, 506
- therapeutic evaluation in, 101-110, 284
- thermolabile inhibition in, 462
- transmission of, 437
- visceral lesions in, 242
- Rheumatoid factor
absorption of preparations, 439
agglutination tests for, 431
binding to cellular elements, 450
cellular origin of, 262
dextran interaction with, 443
and gamma globulin, reaction between, 16-24, 444
hereditary factors in, 446
in hypogammaglobulinemia with rheumatoid arthritis, 274
inhibition of activity, 43
and latex agglutination, 435
and particulate carrier reactions, 515-520
- Rheumatoid hand, surgery of, 437
- Rheumatoid heart disease, 298-307
- Rheumatoid serologic reactions in animals, 28-39
- Rheumatoid spondylitis. *See* Spondylitis, ankylosing
- Ribonuclease (RNase), in tissue preparations, and complement fixation titer, 1-13
- Ribonucleic acid (RNA), production in growing connective tissue, 252
- Roentgen studies. *See* Radiology
- Rubella arthritis, 451
- Salicylates, affecting connective tissue metabolism, 434
- Sarcoidosis, joint involvement in, 453
- Scleroderma
in progressive systemic sclerosis, 536-545
skin mobility in, 429
- Sclerosis, progressive systemic, cutaneous lesion of, 536-545
- Scorbutic animal, collagen synthetic activity in, 252
- Seromucoid, in rheumatic diseases, 49-52
- Serotonin
and connective tissue proliferation, 447
and redox activity of platelets, 452
- Sheep cells
agglutination tests, 26-39
in Sjogren's syndrome, 288
stabilizers and inhibitors in, 266, 314-326
- tannic acid-treated, coating of, 42
- Sialic acids, 250
in rheumatic diseases, 49-52

- Sjegren's syndrome
 anti-cytoplasmic factors in sera of patients with, 1-13
 serologic reactions in, 283, 287-295
 vascular lesions and immunological reactions in, 433
- Skin
 dermatomyositis, 60, 379-385
 mobility in scleroderma, 429
 in progressive systemic sclerosis, 536-545
 in Reiter's syndrome, 469
 test, in lupus erythematosus, 431
- Social factors in rheumatoid arthritis, 456
- Sodium balance
 after cortisone therapy cessation, 209
 after dexamethasone, 132-135
- Spine
 lesions in rheumatoid arthritis and ankylosing spondylitis, 446, 454, 546-555
 osteochondritis in twins, with ankylosing spondylitis, 444
- Splinting, in rheumatoid arthritis, 462
- Spondylitis, ankylosing
 cervical spine lesions in, 446, 454, 546-555
 early characteristics of, 459
 leukemia after x-ray therapy in, 64-74
 roentgen features of, 441
 as separate entity, 88-90
 in twins, with spinal osteochondritis, 444
 ulcerative colitis with, 76-86, 282
 visceral lesions in, 242
- Sponges, polyvinyl, connective tissue development in, 433
- Steroid excretion, after cortisone therapy cessation, 212-213
- Steroids
 abrupt cessation of, 204-216
 cataracts after, 432
 effects on blood vessels, 457
 effects on connective tissue metabolism, 434
 long-term, study of, 451
 peptic ulcer after, 442
 physiologic effects of, 129-138
 pituitary-adrenal function after, 240
- Stiff-man syndrome, 229-231
- Stiffness
 in connective tissue disorders, 255
 measurement of, 328-338
- Streptobacillus moniliformis, joint lesions from, 26-39
- Streptococcal pharyngitis, and rheumatic fever, 464
- Streptococci, fluorescent antiserum identifying, 261
- Sulfapyrazone, uricosuric effects of, 482
- Suppurative arthritis, acute, 522-534
- Surgery
 of rheumatoid hand, 437
 sympathetic denervation in intractable pain, 450
- Sympathetic denervation, in intractable pain, 450
- Synovial cell cultures, 267
- Synovial fluid
 in arthritis with urethritis, 395-401
 carbohydrates of, 409-413
 cell count in, 365
 examination, in arthritis, 364-367
 glucose concentration in, 496
 gouty, urate crystals in, 454
 hyaluronate isolation from, 247
 latex agglutination in, 447
 protein in, and hyaluronic acid, 459
- Synovial membrane, lining cells of, staining of, 448
- Synovial tissue
 cells from, chromosomes in, 436
 cellular components, 142-146
 fibrillar components, 146-148
 ground substance, 146
 microscopic structure of, 140-150
 phenylbutazone affecting, 445
 and popliteal space masses, 218-228
- Synovium
 inflammation, clinical index of, 49-52
 permeability to protein, 152-157
- Therapy of rheumatoid arthritis, evaluation of, 101-110, 284
- Thiocyanate, entrance into joints, 498, 501
- Thoracic disease, and hypertrophic osteoarthropathy, 443
- Thrombophlebitis of leg veins, differential diagnosis of, 218-228
- Thymus antigen, in attempted experimental lupus erythematosus, 403-407, 439
- Thyroid function, dexamethasone affecting, 115-119
- Traumatic arthritis, acute phase reactants in, 49-52
- Triamcinolone, peptic ulcer after, 442
- Trimethadione, lupus erythematosus after, 464
- Trimethylcolchicinic acid (TMCA), in gout, 469
- Trypsin, in tissue preparations, and complement fixation titer, 1-13
- Tumor regression, and mycoplasmal polyarthritides, 260
- Twins
 rheumatoid arthritis, 182-183
 spinal osteochondritis in, with ankylosing spondylitis, 444
- Ulcers
 leg, in rheumatoid arthritis, therapy of, 430
 peptic, after corticosteroids, 442
- UML 491, effects on connective tissue, 448
- Urate crystals, in gouty synovial fluid, 454
- Urethritis
 arthritis with, PPLO in, 395-401
 and Reiter's disease, 164-169
- Uric acid
 after glycine in gout, 448
 fasting affecting excretion, 280
 hyperuricemia in Filipinos, 440
 hyperuricemia in gout, 414-419
- Uricosuric effect of keto analogue of oxyphenbutazone, 281, 475-483

- Vascular conditions
in dermatomyositis, 379-385
in experimental cold injury and rheumatoid disease, 453
periarteritis nodosa, 456
in Sjogren's syndrome, 433
steroid therapy affecting blood vessels, 457
- Venereal urethritis with arthritis, 309-312, 395-401
- Vertebra. *See Spine*
- Vitamin A, and cartilage matrix depletion, 523
- Wassermann reaction, false positive, serum factors in, 2
- Water excretion, after dexamethasone, 132-135
- Whipple's disease, connective tissue in, 438
- X-rays. *See Radiation*
- Xylose, entrance into joints, 503
- Zoxazolamine, uricosuric effects of, 482